Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Purpose
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Condition
- Malignant Solid Neoplasm
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up - For men who are sexually active, the need for use of medically acceptable contraception will be dictated by the primary treatment plan/protocol - Study accrual was closed to women on 08/18/2021 and accrual is now only open to males in order to meet accrual goals and study objectives. (11-AUG-2021) - Male sex - Any patients who will receive treatment with intravenous carboplatin (any AUC, any cycle) on a National Cancer Institute (NCI)-sponsored National Clinical Trial Network (NCTN)-, Experimental Therapeutics Clinical Trials Network (ETCTN)-, trial, local trial, or through standard of care - Age >= 18 - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
Exclusion Criteria
- Treated at an institute where creatinine is not measured with an IDMS calibrated assay - History of allergic reactions to computed tomography (CT) contrast, iodine or shellfish, or history of anaphylactic reaction to any food item - Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or have current indwelling nephrostomy tubes - Edema beyond trace edema, because this will impact iohexol equilibration and distribution - Ascites (including pleural effusion) beyond trace ascites, because this will impact iohexol equilibration and distribution - Whole- or part-limb amputees, because this will impact iohexol equilibration and distribution - Inability to maintain a constant dose and schedule of anti-inflammatory agents, diuretics, angiotensin II receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi) for one week prior to study visit, as this impacts renal function. If the patient is on a nonsteroidal anti-inflammatory drug (NSAID), diuretic, ARB or ACEi, they are eligible as long as these agents are taken on a set schedule for 7 or more days prior to study (and not on an "as needed" basis as that can cause fluctuations in renal function) - Inadequate venous access to obtain pharmacokinetic (PK) specimens - Multinodular goiter, Graves' disease or autoimmune thyroiditis, per iohexol package insert (hypothyroidism is allowed)
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Treatment (iohexol, standard care carboplatin, blood samples) |
Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis. |
|
Recruiting Locations
Tucson, Arizona 85704
Site Public Contact
520-694-8900
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Encinitas, California 92024
Site Public Contact
760-536-7700
La Jolla, California 92093
Sacramento, California 95817
Site Public Contact
916-734-3089
San Diego, California 92103
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Greeley, Colorado 80631
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Savannah, Georgia 31405
Boise, Idaho 83706
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Emmett, Idaho 83617
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Alton, Illinois 62002
Site Public Contact
618-463-5623
Centralia, Illinois 62801
Chicago, Illinois 60611
Danville, Illinois 61832
Effingham, Illinois 62401
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Mattoon, Illinois 61938
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
Urbana, Illinois 61801
Urbana, Illinois 61801
Richmond, Indiana 47374
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Carroll, Iowa 51401
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
Fort Dodge, Iowa 50501
Site Public Contact
515-574-8302
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
Garden City, Kansas 67846
Great Bend, Kansas 67530
Baltimore, Maryland 21287
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Springfield, Massachusetts 01199
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Bolivar, Missouri 65613
Branson, Missouri 65616
Site Public Contact
417-269-4520
Joplin, Missouri 64804
Joplin, Missouri 64804
Osage Beach, Missouri 65065
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63109
Site Public Contact
314-353-1870
Saint Louis, Missouri 63128
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Washington, Missouri 63090
Site Public Contact
636-390-1600
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Las Vegas, Nevada 89106
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Sewell, New Jersey 08080
Somerville, New Jersey 08876
Bronx, New York 10461
Bronx, New York 10461
Bronx, New York 10467
Buffalo, New York 14263
Commack, New York 11725
Site Public Contact
212-639-7592
East Hills, New York 11548
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14620
Site Public Contact
585-341-8113
Rochester, New York 14642
Site Public Contact
585-275-5830
Syracuse, New York 13210
Site Public Contact
315-464-5476
Uniondale, New York 11553
Site Public Contact
212-639-7592
West Islip, New York 11795
Site Public Contact
516-326-7514
Beavercreek, Ohio 45431
Boardman, Ohio 44512
Centerville, Ohio 45459
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Cincinnati, Ohio 45236
Columbus, Ohio 43210
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Findlay, Ohio 45840
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Greenville, Ohio 45331
Kettering, Ohio 45409
Kettering, Ohio 45429
Troy, Ohio 45373
Troy, Ohio 45373
Warren, Ohio 44484
West Chester, Ohio 45069
Youngstown, Ohio 44501
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Baker City, Oregon 97814
Ontario, Oregon 97914
Philadelphia, Pennsylvania 19107
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Franklin, Tennessee 37067
Site Public Contact
800-811-8480
Franklin, Tennessee 37067
Site Public Contact
800-811-8480
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Cody, Wyoming 82414
Sheridan, Wyoming 82801
Bayamon, Puerto Rico 00959-5060
Site Public Contact
787-395-7085
Bayamon, Puerto Rico 00961
Site Public Contact
787-780-2865
Manati, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan, Puerto Rico 00917
Site Public Contact
787-274-3387
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT03997370
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate the success of targeting a carboplatin area under the curve (AUC) with our current approach to dosing carboplatin. II. Assess the performance of Cockcroft-Gault (CG), four-variable Modification of Diet in Renal Disease (MDRD-4), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) based on isotope dilution mass spectrometry (IDMS) calibrated serum creatinine in predicting measured glomerular filtration rate (mGFR) in patients with cancer. III. Define the relationship of mGFR and carboplatin clearance in patients with cancer. SECONDARY OBJECTIVES: I. Evaluate the divergence of estimated (e)GFR from mGFR based on patient demographic and other characteristics, thus identifying those most likely to benefit from determination of mGFR over use of eGFR. II. Determine the success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped. III. Evaluate the relationship between carboplatin exposure and toxicity. IV. Assess the ability of markers other than creatinine in pre-treatment serum to better estimate kidney function in patients with cancer. OUTLINE: Patients receive iohexol intravenously (IV) over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis. After completion of study, patients are followed up for 3-4 weeks.